triple negative breast cancer

FDA Approves Immunomedics' Breast Cancer Drug
FDA Approves Immunomedics' Breast Cancer Drug
Motley Fool
FDA
Immunomedics
triple negative breast cancer
Trodelvy
Flag link:
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
BioSpace
Rexahn
triple negative breast cancer
Merck
Keytruda
Flag link:
Immunomedics' Triple-Negative Breast Cancer Trial Halted Early Due to Compelling Efficacy
Immunomedics' Triple-Negative Breast Cancer Trial Halted Early Due to Compelling Efficacy
BioSpace
Immunomeedics
sacituzumab govitecan
clinical trials
breast cancer
triple negative breast cancer
Flag link:
How Gilead's blood cancer med Zydelig might also address triple-negative breast cancer
How Gilead's blood cancer med Zydelig might also address triple-negative breast cancer
Fierce Biotech
Gilead Sciences
Zydelig
breast cancer
triple negative breast cancer
Flag link:
Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
Endpoints
Merck
Keytruda
triple negative breast cancer
clinical trials
Roche
Flag link:
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
Endpoints
Roche
Tecentriq
FDA
Europe
Celgene
Abraxane
triple negative breast cancer
Flag link:
CRISPR slows the growth of triple-negative breast cancer in mice
CRISPR slows the growth of triple-negative breast cancer in mice
Fierce Biotech
Boston Children's Hospital
CRISPR
gene editing
Lipocalin 2
triple negative breast cancer
Flag link:
Merck Data Are Another Step for Immunotherapy in Breast Cancer
Merck Data Are Another Step for Immunotherapy in Breast Cancer
Xconomy
Merck
Keytruda
clinical trials
triple negative breast cancer
Flag link:
Roche closes on EU approval for Tecentriq in breast cancer
Roche closes on EU approval for Tecentriq in breast cancer
Pharmaforum
Roche
Tecentriq
Europe
triple negative breast cancer
Flag link:
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Fierce Biotech
ASCO 2019
Ayala Pharmaceuticals
Novartis
triple negative breast cancer
AL101
Flag link:
Merck’s Keytruda fails in triple negative breast cancer trial
Merck’s Keytruda fails in triple negative breast cancer trial
Pharmaforum
Merck
Keytruda
clinical trials
triple negative breast cancer
Flag link:
Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer
Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer
First Word Pharma
Roche
Genentech
FDA
Tecentriq
triple negative breast cancer
Flag link:
Phoenix, Roche partner to develop TNBC biomarker
Phoenix, Roche partner to develop TNBC biomarker
BioCentury
Roche
Phoenix Molecular Designs
diagnostics
molecular diagnostics
triple negative breast cancer
biomarkers
Flag link:
A Spark Of Good News For Precision Oncology In Breast Cancer
A Spark Of Good News For Precision Oncology In Breast Cancer
Forbes
AstraZeneca
triple negative breast cancer
AZD5363
precision medicine
Flag link:
Roche’s Tecentriq gets fast review in triple negative breast cancer
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Roche
Genentech
Tecentriq
Celgene
Abraxane
FDA
triple negative breast cancer
Flag link:
Benefit of Roche's Tecentriq looks limited in breast cancer
Benefit of Roche's Tecentriq looks limited in breast cancer
Biopharma Dive
Roche
Tecentriq
breast cancer
triple negative breast cancer
Flag link:
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
CP Wire
TrovaGene
Onvansertib
AML
mCRPC
non-Hodgkin lymphoma
triple negative breast cancer
Flag link:
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Flag link:
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Endpoints
Roche
Tecentriq
Genentech
triple negative breast cancer
Celgene
Abraxane
Flag link:
OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial
OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial
Drug Delivery Business News
OncoSec Medical
Merck
ImmunoPulse IL-12
Keytruda
triple negative breast cancer
Flag link:

Pages